Synairgen Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 33

Employees

  • Stock Symbol
  • OMY

Stock Symbol

Synairgen General Information

Description

Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.

Contact Information

Website
www.synairgen.com
Formerly Known As
Synairgen Research
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Mailpoint 810
  • Southampton General Hospital, Tremona Road
  • Southampton SO16 6YD
  • England, United Kingdom
+44 023
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Stock Exchange
FRA
Corporate Office
  • Mailpoint 810
  • Southampton General Hospital, Tremona Road
  • Southampton SO16 6YD
  • England, United Kingdom
+44 023

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synairgen Stock Performance

As of 08-Apr-2025, Synairgen’s current market cap is $8.42M with 1.1B shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.42M 1.1B 7.16K -$0.03

Synairgen Financials Summary

As of 30-Jun-2024, Synairgen has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (4,613) (3,135) 10,913 501,319
Revenue 0 0 0 0
EBITDA (10,874) (12,689) (24,893) (79,306)
Net Income (8,716) (10,451) (21,747) (66,918)
Total Assets 13,457 18,116 28,475 60,245
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Synairgen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Synairgen‘s full profile, request access.

Request a free trial

Synairgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in th
Drug Discovery
Southampton, United Kingdom
33 As of 2023

London, United Kingdom
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synairgen Competitors (31)

One of Synairgen’s 31 competitors is Verona Pharma, a Private Debt Financed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Verona Pharma Private Debt Financed London, United Kingdom
Ventus Therapeutics Venture Capital-Backed Waltham, MA
Pulmatrix Formerly VC-backed Framingham, MA
Theravance Biopharma Corporation San Francisco, CA
Savara Formerly VC-backed Langhorne, PA
You’re viewing 5 of 31 competitors. Get the full list »

Synairgen Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 11

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Synairgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202106014-D0 Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients Inactive 27-Apr-2021
US-20230241177-A1 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid Pending 08-Sep-2020
GB-202014114-D0 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid Inactive 08-Sep-2020
EP-4210728-A1 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid Pending 08-Sep-2020
GB-202011284-D0 Use of inhaled interferon-beta to improve outcome in sars-cov-2 infected patients Inactive 21-Jul-2020
To view Synairgen’s complete patent history, request access »

Synairgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synairgen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Synairgen‘s full profile, request access.

Request a free trial

Synairgen ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Synairgen’s complete esg history, request access »

Synairgen FAQs

  • When was Synairgen founded?

    Synairgen was founded in 2003.

  • Where is Synairgen headquartered?

    Synairgen is headquartered in Southampton, United Kingdom.

  • What is the size of Synairgen?

    Synairgen has 33 total employees.

  • What industry is Synairgen in?

    Synairgen’s primary industry is Drug Discovery.

  • Is Synairgen a private or public company?

    Synairgen is a Public company.

  • What is Synairgen’s stock symbol?

    The ticker symbol for Synairgen is OMY.

  • What is the current market cap of Synairgen?

    The current market capitalization of Synairgen is $8.42M.

  • Who are Synairgen’s competitors?

    Verona Pharma, Ventus Therapeutics, Pulmatrix, Theravance Biopharma, and Savara are some of the 31 competitors of Synairgen.

  • What is Synairgen’s annual earnings per share (EPS)?

    Synairgen’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »